Graphite Bio, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

170.39 k

Shareholding (Mar 2025)

FII

7.28%

Held by 44 FIIs

DII

80.91%

Held by 12 DIIs

Promoter

1.98%

How big is Graphite Bio, Inc.?

22-Jun-2025

As of Jun 18, Graphite Bio, Inc. has a market capitalization of 796.43 million and reported net sales of 0.00 million with a net profit of -47.73 million over the last four quarters. Shareholder's funds were 204.08 million, and total assets were 215.30 million.

What does Graphite Bio, Inc. do?

22-Jun-2025

Graphite Bio, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, currently reporting a net profit loss of $15 million and a market cap of $796.43 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -24.86%.

Is Graphite Bio, Inc. overvalued or undervalued?

20-Sep-2025

As of July 30, 2025, Graphite Bio, Inc. is considered risky and overvalued due to negative financial metrics, despite strong stock performance, especially when compared to its peer, Stoke Therapeutics, Inc.

Is Graphite Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, Graphite Bio, Inc. has shifted to a bullish trend, supported by positive indicators like the MACD, Bollinger Bands, and moving averages, while outperforming the S&P 500 with a year-to-date return of 44.41% compared to 12.22%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 8.61%, its profits have risen by 31.4%

Reducing Promoter Confidence

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,102 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-25.39%

Price to Book

5.34

Revenue and Profits:

Net Sales:

5 Million

(Quarterly Results - Jun 2025)

Net Profit:

-15 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-28.95%

6 Months

-6.28%

1 Year

-21.91%

2 Years

76.36%

3 Years

697.14%

4 Years

-54.81%

5 Years

0.0%

Graphite Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Graphite Bio, Inc. technically bullish or bearish?

As of 5 August 2025, the technical trend for Graphite Bio, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and Bollinger Bands are also indicating a bullish stance. Daily moving averages confirm a bullish trend, while the KST shows bullish momentum on both weekly and monthly time frames. The Dow Theory reflects a mildly bullish outlook on both weekly and monthly periods. Despite the lack of signals from the RSI, the overall technical indicators suggest a strong bullish position. In terms of performance, the stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 44.41% compared to the S&P 500's 12.22%, and a one-year return of 93.91% versus 17.14%....

Is Graphite Bio, Inc. overvalued or undervalued?

As of 30 July 2025, the valuation grade for Graphite Bio, Inc. has moved from does not qualify to risky, indicating increased concerns about its financial health. The company appears to be overvalued given its significant negative metrics, including a price-to-book value of 4.58 and a return on equity of -24.86%. Additionally, the EV to EBITDA ratio stands at -11.54, highlighting the challenges in generating positive earnings. In comparison to its peer, Stoke Therapeutics, Inc., which has a fair valuation with a P/E ratio of 22.96 and an EV to EBITDA of 21.50, Graphite Bio's ratios suggest a less favorable position in the market. Despite this, Graphite Bio has shown strong stock performance, with a year-to-date return of 44.41% compared to the S&P 500's 12.22%, and a one-year return of 93.91% versus the S&P 500's 17.14%. This strong performance may not be sustainable given the underlying financial metrics,...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-24.51%

EBIT Growth (5y)

-257.07%

EBIT to Interest (avg)

-55.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

83.76%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.58

EV to EBIT

-11.53

EV to EBITDA

-11.54

EV to Capital Employed

-436.25

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-24.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 30 Schemes (9.84%)

Foreign Institutions

Held by 44 Foreign Institutions (7.28%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -44.66% vs 81.37% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-16.80",
          "val2": "-14.30",
          "chgp": "-17.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.90",
          "val2": "-10.30",
          "chgp": "-44.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,371.40%",
          "val2": "0.00%",
          "chgp": "-337.14%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 28.86% vs 30.76% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-58.60",
          "val2": "-72.40",
          "chgp": "19.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.80",
          "val2": "-70.00",
          "chgp": "28.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

5.00

0.00

Operating Profit (PBDIT) excl Other Income

-16.80

-14.30

-17.48%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.90

-10.30

-44.66%

Operating Profit Margin (Excl OI)

-3,371.40%

0.00%

-337.14%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -44.66% vs 81.37% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-58.60

-72.40

19.06%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-49.80

-70.00

28.86%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 28.86% vs 30.76% in Dec 2023

All Annual Results

Company CV

About Graphite Bio, Inc.

Graphite Bio, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Graphite Bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Graphite Bio, Inc.?

Watch in Real-Time

What does Graphite Bio, Inc. do?

Is Graphite Bio, Inc. overvalued or undervalued?

Is Graphite Bio, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Risky - Negative EBITDA

Reducing Promoter Confidence

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Graphite Bio, Inc. technically bullish or bearish?

Is Graphite Bio, Inc. overvalued or undervalued?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Graphite Bio, Inc.

Company Coordinates